@article{oai:repo.qst.go.jp:00082621,
 author = {Yasuhiro, Oshima and Yasuhiro, Oshima},
 journal = {QST Takasaki Annual Report 2019},
 month = {Mar},
 note = {Positron emission tomography (PET) with amino acid analogs has great impacts on the treatment of cancer by diagnosis, staging, and monitoring. Among them, 3-18F-fluoro-α-methyl-L-tyrosine (18F-FAMT) has been routinely used for tumor diagnosis in Gunma University Hospital. The specific accumulation of 18F-FAMT in malignant tumors is exclusively promoted by L-type amino acid transporter 1 (LAT1), the expression of which is highly upregulated in many types of cancers. However, a major drawback of 18F-FAMT PET is the relatively high frequency of false-negative results because of its low tumor accumulation level. These clinical findings have prompted the further development of 18F-FAMT analogs with higher tumor accumulation and improved pharmacokinetics. In this study, we prepared 18F-FAMP regioisomers (2-, 3-, or 4-18F-FAMP) and stereoisomers (L- or D-form), and we comprehensively evaluated their potential as tumor-imaging agents.},
 pages = {16--16},
 title = {Novel 18F-labeled α-methyl-phenylalanine derivative with high tumor accumulation and ideal pharmacokinetics for tumor-specific imaging},
 year = {2021}
}